New drug trial offers hope for Tough-to-Treat lymphomas
NCT ID NCT07249905
Summary
This early-stage study is testing an experimental drug called MDX2003 for people with several types of B-cell lymphoma that have come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. It will enroll about 180 adults who have measurable disease and whose cancer tests positive for certain markers (CD19 or CD20).
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.